Skip to main content

Articles Tagged With:

  • Report from Europe

    A team of French physicians said it has proof of principle that autologous cell therapy is a viable treatment for myocardial infarction.
  • Agreements

    Digital Angel (South St. Paul, Minnesota) said it is working closely with the University of California at Riverside School of Engineering to accelerate the integration of medical and environmental biosensor technologies into its expanding line of wireless communications devices.
  • Market updates

    A Medicare advisory panel recommendation to cover implantable cardioverter defibrillators (ICDs) could be a major victory for companies such as Guidant (Indianapolis, Indiana), Medtronic (Minneapolis, Minnesota) and St. Jude Medical (St. Paul, Minnesota).
  • Personnel File

    George Daniloff, MD, PhD, has been named general manager and vice president of research and development of the California facility of Angiotech Pharmaceuticals (Vancouver, British Columbia).
  • Product Pipeline

    A third player has entered the drug-eluting stent sector in Europe, though the company claims it was really the second firm to earn the CE mark. While that may be the case, the real question may be the devices speed of entry to U.S. launch.
  • Full March 1, 2003 Issue in PDF

  • CardioGenesis reports impressive results

    SAN DIEGO, California When introduced to the U.S. market in the summer of 1998, many industry observers expected that transmyocardial revascularization (TMR) would be adopted rapidly by the cardiac surgery community.
  • Acquisitions

    Angiotech Pharmaceuticals (Vancouver, British Columbia) reported completing its purchase of biomaterials engineering and biosurgical products manufacturer Cohesion Technologies (Palo Alto, California).
  • Business Developments

    The cardiovascular field last month saw the unveiling of a couple of significant new developments in the cardiovascular arena, one a study for a combination medical device/biotechnology therapy for the enhancement of revascularization and the other a pivotal trial for a self-expanding carotid stent system.
  • So far, so good: As vaccinations begin, few serious smallpox reactions emerge

    Screening adds safety to smallpox vaccination. Despite widespread fears about the smallpox vaccine, there were few serious adverse reactions and no known spread to contacts in the first month of the vaccination program.